For the first 10 patients suffering from bullous pemphigoid included at the Nîmes University Hospital only; Skin biopsy, plasma and circulating mononuclear cell DNA expression for the pan-alpha, alpha6, beta1, beta2, beta1i, beta5i and rpt5 subunits (weighted by beta-actin)

Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid

Official Title ICMJE

Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid

Brief Summary

The primary objective of this study is to describe and compare plasmatic anti-proteasome auto-antibody concentrations among three distinct groups: (1) patients suffering from bullous pemphigoide; (2) patients suffering from other dermatological auto-immune diseases; (3) an elderly control group.

To characterize the expression and the activity of proteasomes in skin samples, in plasma and in circulating mononuclear cells in patients with bullous pemphigoide.

Study Type ICMJE

Observational

Study Design ICMJE

Observational Model: CohortTime Perspective: Cross-Sectional

Target Follow-Up Duration

Not Provided

Biospecimen

Retention: Samples With DNA

Description:

All left over plasma samples will be incorporated into the biological collection at the Nîmes University Hospital.

Sampling Method

Non-Probability Sample

Study Population

The study population is composed of three groups: (1) 50 patients with newly diagnosed (untreated) bullous pemphigoid, (2) 50 control patients matched for age and sex with the previous group and (3) 30 patients with other dermatological auto-immune disease (15 pemphigus + 15 cutaneous lupus).

Condition ICMJE

Pemphigoid, Bullous

Pemphigus

Lupus Erythematosus, Cutaneous

Intervention ICMJE

Not Provided

Study Group/Cohort (s)

Bullous pemphigoid

Patients in this cohort are newly diagnosed (or have not started treatment) with bullous pemphigoid

Other bullous-like auto-immune

Patients in this cohort are newly diagnosed (or have not started treatment) with pemphigus (15 patients) or cutaneous lupus (15 patients)

Control group

Patients in this cohort are hospitalized at the Nîmes University Hospital, and have no history of autoimmune, inflammatory or neoplastic disease. Patients are matched for age and sex with patients in the bullous pemphigoid cohort.

Publications *

Not Provided

* Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.